SuspendedNCT06876142
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
PHASE1 · PHASE2 · 54 planned enrolment
- Countries listed
- 1
- Registry update
- October 7, 2026
Registry Intervention View
sirolimus
Trial registrations containing the exact intervention label sirolimus.
Exact registry label · Not reported
28 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
10 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
Active Not RecruitingNCT02979873
Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy
PHASE2 · 84 planned enrolment
- Countries listed
- 1
- Registry update
- October 6, 2026
RecruitingNCT07162038
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
PHASE1 · 155 planned enrolment
- Countries listed
- 1
- Registry update
- September 21, 2026
RecruitingNCT05327023
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
PHASE1 · PHASE2 · 430 planned enrolment
- Countries listed
- 1
- Registry update
- September 18, 2026
RecruitingNCT05436418
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
PHASE1 · PHASE2 · 260 planned enrolment
- Countries listed
- 1
- Registry update
- September 11, 2026
Enrolling By InvitationNCT07113743
Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
PHASE1 · PHASE2 · 10 planned enrolment
- Countries listed
- 1
- Registry update
- September 8, 2026
RecruitingNCT06325709
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
PHASE1 · PHASE2 · 15 planned enrolment
- Countries listed
- 1
- Registry update
- August 13, 2026
RecruitingNCT05237687
The Role of Sirolimus in Preventing Functional Decline in Older Adults
PHASE2 · 10 planned enrolment
- Countries listed
- 1
- Registry update
- June 25, 2026
RecruitingNCT04959175
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
PHASE1 · PHASE2 · 320 planned enrolment
- Countries listed
- 1
- Registry update
- June 11, 2026
RecruitingNCT05949658
Rapalog Pharmacology (RAP PAC) Study
PHASE1 · 72 planned enrolment
- Countries listed
- 1
- Registry update
- May 28, 2026
Active Not RecruitingNCT06752694
Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
PHASE2 · 1 planned enrolment
- Countries listed
- 1
- Registry update
- May 22, 2026
Active Not RecruitingNCT05088356
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
PHASE1 · 66 planned enrolment
- Countries listed
- 1
- Registry update
- May 12, 2026
WithdrawnNCT05170828
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
PHASE1 · 0 planned enrolment
- Countries listed
- 0
- Registry update
- February 24, 2026
Active Not RecruitingNCT04789070
Phase III Trial of Sirolimus in IBM
PHASE3 · 140 planned enrolment
- Countries listed
- 3
- Registry update
- January 14, 2026
CompletedNCT01184885
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
EARLY_PHASE1 · 7 planned enrolment
- Countries listed
- 1
- Registry update
- May 4, 2025
CompletedNCT00406393
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
PHASE3 · 304 planned enrolment
- Countries listed
- 2
- Registry update
- January 4, 2023
CompletedNCT00350181
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
PHASE2 · 11 planned enrolment
- Countries listed
- 1
- Registry update
- September 23, 2021
CompletedNCT02440789
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)
PHASE1 · PHASE2 · 32 planned enrolment
- Countries listed
- 1
- Registry update
- August 3, 2021
CompletedNCT01445548
Sirolimus for Advanced Age-Related Macular Degeneration
PHASE1 · PHASE2 · 6 planned enrolment
- Countries listed
- 1
- Registry update
- July 7, 2021
CompletedNCT00766649
Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD
PHASE1 · PHASE2 · 11 planned enrolment
- Countries listed
- 1
- Registry update
- July 14, 2020
CompletedNCT01791088
Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
PHASE1 · 56 planned enrolment
- Countries listed
- 1
- Registry update
- April 22, 2019
CompletedNCT03072485
Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers
PHASE1 · 10 planned enrolment
- Countries listed
- 1
- Registry update
- April 1, 2019
CompletedNCT02732899
Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD
PHASE2 · 20 planned enrolment
- Countries listed
- 1
- Registry update
- February 14, 2018
CompletedNCT02357342
Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
PHASE2 · 40 planned enrolment
- Countries listed
- 1
- Registry update
- June 22, 2017
TerminatedNCT01220297
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
PHASE2 · 3 planned enrolment
- Countries listed
- 1
- Registry update
- June 5, 2017
TerminatedNCT01675947
Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy
PHASE2 · 52 planned enrolment
- Countries listed
- 1
- Registry update
- December 10, 2015
TerminatedNCT00712491
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
PHASE1 · PHASE2 · 20 planned enrolment
- Countries listed
- 1
- Registry update
- January 10, 2013
CompletedNCT00129961
Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
PHASE4 · 86 planned enrolment
- Countries listed
- 4
- Registry update
- April 11, 2012